Xenon and Sionna Shares Plunge as Inverse Crypto ETFs Face Steep Losses

Key Facts

1Xenon Pharmaceuticals shares dropped 30.71% after pausing enrollment in depression studies due to safety concerns.

2Sionna Therapeutics fell 17.27% amid ongoing pressure from a clinical study failure and workforce restructuring.

3Inverse crypto ETFs posted substantial losses following sharp rallies in Coinbase and Strategy Inc. shares.

Amid heightened volatility in the biotech and digital asset sectors, several instruments faced intense selling pressure due to clinical setbacks and shifting market momentum. Xenon Pharmaceuticals shares dropped 30.71% after the company paused enrollment in its azetukalner studies for depression due to safety concerns and neurological side effects. Similarly, Sionna Therapeutics fell 17.27% as the company continues to reel from a prior clinical failure and a workforce restructuring that impacted 46% of its staff.

Crypto-linked financial instruments were also directly impacted by movements in sector leaders, with inverse crypto ETFs posting substantial losses. This decline followed sharp rallies in shares of Coinbase and Strategy Inc., which triggered heavy losses for investors betting against these assets. Per market data, these inverse funds saw double-digit percentage drops as the underlying crypto-linked equities moved higher.

At the close on September 17, 2026, XENE stood at $57.35 and SION at $7.18, while COIN closed at $173.97 and MSTR at $132.25. Investors should watch for further updates regarding Xenon's clinical safety profile and monitor upcoming global economic catalysts, including the BCB Focus Market Readout and Canadian inflation data scheduled for the coming days.